Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Harrow Inc (HROW)

Harrow Inc (HROW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030 GlobeNewswire - Tue Mar 24, 3:57PM CDT

NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the pricing of its private...

HROW : 33.30 (-1.57%)
Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth GlobeNewswire - Tue Mar 24, 7:15AM CDT

NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it intends to offer,...

HROW : 33.30 (-1.57%)
Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting GlobeNewswire - Wed Mar 18, 6:00AM CDT

NASHVILLE, Tenn., March 18, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that three scientific abstracts...

HROW : 33.30 (-1.57%)
Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conference GlobeNewswire - Wed Mar 4, 6:00AM CST

NASHVILLE, Tenn., March 04, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present...

HROW : 33.30 (-1.57%)
Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication GlobeNewswire - Tue Mar 3, 6:00AM CST

NASHVILLE, Tenn., March 03, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that the U.S. Food and Drug...

HROW : 33.30 (-1.57%)
Harrow: Q4 Earnings Snapshot AP - Mon Mar 2, 4:08PM CST

Harrow: Q4 Earnings Snapshot

HROW : 33.30 (-1.57%)
Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance GlobeNewswire - Mon Mar 2, 3:05PM CST

Fourth Quarter, Full-Year 2025 and Selected Highlights:  Record quarterly revenue of $89.1 million, a 33% increase over $66.8 million recorded in the prior-year period Full-Year revenue of $272.3...

HROW : 33.30 (-1.57%)
Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026 GlobeNewswire - Wed Feb 18, 6:00AM CST

NASHVILLE, Tenn., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial...

HROW : 33.30 (-1.57%)
Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits GlobeNewswire - Tue Feb 17, 6:00AM CST

NASHVILLE, Tenn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of a new Direct-to-Prescriber...

HROW : 33.30 (-1.57%)
Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth GlobeNewswire - Mon Feb 2, 6:00AM CST

Doubling of VEVYE® Sales Force is On Track, Expansion of IHEEZO® Commercial Footprint to  the Office-Based Setting Underway, and Doubling TRIESENCE® Commercial Footprint in the Surgical-Based...

HROW : 33.30 (-1.57%)

Barchart Exclusives

2 Reasons Why Wells Fargo Thinks You Should Buy Google Stock Now Barchart - 54 minutes ago
2 Reasons Why Wells Fargo Thinks You Should Buy Google Stock Now Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.